Ann: Receipt of R&D Tax Incentive, page-9

A share consolidation and a capital raising without very good news is never[in my opinion] going to work,especially with an unresolved outstanding legal damages claim still not resolved.Even major shareholders are not going to put more into this company under this current obscure situation.
POH was valued by NDF Research prior to the arbitration issue at between 6c and 9c per share[excluding the arbitration result and applying no value to animal health projects].The present 0.3c share price means that virtually all value of anything POH has been wiped off.
Terumo clearly see value in the propofol injectable and other injectable projects through joint patents etc.
[FWIW in the past I have enquired as to whether Terumo and POH were working on a daptomycin injectable and I received a definite NO response]
The patches and any value are too far away in terms of clinical development to help save POH and I have thus come to the conclusion that Terumo[and injectables] is the most likely and ever so slim chance of being the POH get out of jail card.
Kens